Spots Global Cancer Trial Database for trifluridine and tipiracil hydrochloride

Every month we try and update this database with for trifluridine and tipiracil hydrochloride cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer	NCT03992456	Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... Unresectable Co... Unresectable Co... Unresectable Re...	Panitumumab Quality-of-Life... Questionnaire A... Regorafenib Trifluridine an...	18 Years -	Academic and Community Cancer Research United
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma	NCT04097028	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Trifluridine an... Oxaliplatin	18 Years -	Roswell Park Cancer Institute
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma	NCT04097028	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag...	Trifluridine an... Oxaliplatin	18 Years -	Roswell Park Cancer Institute
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer	NCT04294264	Metastatic Colo... Recurrent Colon... Refractory Colo... Stage IV Colon ... Stage IVA Colon... Stage IVB Colon...	Oxaliplatin Trifluridine an...	18 Years -	Rutgers, The State University of New Jersey
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer	NCT04104139	Rectal Adenocar... Stage IIA Recta... Stage IIB Recta... Stage III Recta... Stage IIIA Rect... Stage IIIB Rect... Stage IIIC Rect...	3-Dimensional C... Intensity-Modul... Trifluridine an...	18 Years -	OHSU Knight Cancer Institute
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer	NCT03981614	Metastatic Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Ca...	Binimetinib Palbociclib Trifluridine an...	18 Years -	Academic and Community Cancer Research United
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer	NCT04511039	Advanced Malign... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Metastatic Colo... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color...	Trifluridine an... Talazoparib Tos...	18 Years -	Roswell Park Cancer Institute
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer	NCT03981614	Metastatic Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Ca...	Binimetinib Palbociclib Trifluridine an...	18 Years -	Academic and Community Cancer Research United
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer	NCT04294264	Metastatic Colo... Recurrent Colon... Refractory Colo... Stage IV Colon ... Stage IVA Colon... Stage IVB Colon...	Oxaliplatin Trifluridine an...	18 Years -	Rutgers, The State University of New Jersey
A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer	NCT05130060	Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Micr... Metastatic Micr... Metastatic Rect... Microsatellite ... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color...	Colorectal Canc... Trifluridine an...	18 Years -	Mayo Clinic
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer	NCT04104139	Rectal Adenocar... Stage IIA Recta... Stage IIB Recta... Stage III Recta... Stage IIIA Rect... Stage IIIB Rect... Stage IIIC Rect...	3-Dimensional C... Intensity-Modul... Trifluridine an...	18 Years -	OHSU Knight Cancer Institute
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer	NCT03844620	Refractory Colo... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color...	Best Practice Laboratory Proc... Quality-of-Life... Questionnaire A... Regorafenib Trifluridine an...	18 Years -	M.D. Anderson Cancer Center
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer	NCT04511039	Advanced Malign... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Metastatic Colo... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color...	Trifluridine an... Talazoparib Tos...	18 Years -	Roswell Park Cancer Institute
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study	NCT04109924	Advanced Colore... Metastatic Colo... Metastatic Rect... Recurrent Colon... Recurrent Color... Recurrent Recta... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IV Colon ... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... Unresectable Co... Unresectable Co... Unresectable Re...	Irinotecan Bevacizumab Trifluridine an...	18 Years -	Roswell Park Cancer Institute
Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study	NCT05356897	Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal...	Trastuzumab Trifluridine an... Tucatinib	18 Years -	Academic and Community Cancer Research United
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer	NCT04072445	Advanced Bile D... Advanced Gallbl... Refractory Bile... Refractory Gall... Stage III Dista... Stage III Gallb... Stage III Intra... Stage IIIA Dist... Stage IIIA Gall... Stage IIIA Intr... Stage IIIB Dist... Stage IIIB Gall... Stage IIIB Intr... Stage IV Distal... Stage IV Gallbl... Stage IV Intrah... Stage IVA Gallb... Stage IVB Gallb...	Irinotecan Irinotecan Hydr... Trifluridine an...	18 Years -	Mayo Clinic
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer	NCT04660760	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant...	Paclitaxel Quality-of-Life... Ramucirumab Trifluridine an...	18 Years -	Academic and Community Cancer Research United

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: